RenovoRx's TAMP Platform Shows Promise in Reducing Systemic Exposure in Pancreatic Cancer Trial
Event summary
- RenovoRx presented pharmacokinetic data from a sub-study of its Phase III TIGeR-PaC trial at the 2026 ASCO Annual Meeting.
- The study evaluated the TAMP platform for targeted intra-arterial delivery of gemcitabine via RenovoCath, showing potential to reduce systemic exposure and increase local drug potency.
- Results from 16 patients across six trial sites indicated a direct correlation between increased metabolite levels and reduced CA 19-9 biomarker.
- RenovoRx anticipates full enrollment in the TIGeR-PaC trial by June 2026 and final data readout in mid to late 2027.
The big picture
RenovoRx's TAMP platform represents a strategic shift in targeted oncology therapies, aiming to enhance the efficacy of existing treatments while minimizing systemic side effects. The positive pharmacokinetic data from the TIGeR-PaC trial sub-study positions the company to potentially disrupt the pancreatic cancer treatment landscape, a critical area with high unmet medical needs. The broader industry trend towards precision medicine and targeted drug delivery underscores the significance of RenovoRx's approach.
What we're watching
- Clinical Validation
- Whether the TAMP platform's ability to reduce systemic exposure and increase local drug potency will translate into improved patient outcomes and regulatory approval.
- Commercialization
- The pace at which RenovoRx can expand the commercial use of RenovoCath and its TAMP technology beyond the current trial.
- Regulatory Pathway
- How the FDA will evaluate the combination product candidate (IAG) under the investigational new drug application pathway.
Related topics